Skip to main content

Table 1 Summary of association results of the genome-wide association study

From: A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients

       ADRb   Non-ADRc RAF Pvalue   
CHR SNP Gene Allele 1/2 (risk) 11 12 22 11 12 22 ADR Non-ADR Allelic Dominant Recessive ORa 95% CI
2 rs3820706 CACNB4 A/G (G) 18 169 116 167 421 291 0.66 0.57 8.26E-05 1.07E-01 8.13E-09 3.71 (2.24-6.15)
2 rs6725180 CACNB4 A/C (C) 17 152 134 135 429 316 0.69 0.60 7.90E-05 1.11E-02 3.84E-06 3.05 (1.81-5.14)
8 rs16908658 FAM135B G/A (G) 30 93 180 23 286 571 0.25 0.19 1.07E-03 9.68E-02 9.93E-07 4.09 (2.34-7.17)
10 rs7476422 PCDH15 T/G (G) 4 47 252 34 245 601 0.91 0.82 1.20E-07 3.77E-07 3.58E-02 2.17 (1.60-2.93)
10 rs857373 PCDH15 G/A (A) 5 55 243 43 255 581 0.89 0.81 5.16E-07 3.15E-06 1.11E-02 2.00 (1.51-2.66)
10 rs857392 PCDH15 G/A (A) 5 55 243 42 252 584 0.89 0.81 9.08E-07 5.95E-06 1.60E-02 1.97 (1.48-2.62)
10 rs1319836 PCDH15 C/T (T) 5 55 243 42 254 583 0.89 0.81 9.10E-07 4.34E-06 1.60E-02 1.98 (1.49-2.63)
10 rs7919725 PCDH15 A/G (G) 5 56 242 42 256 580 0.89 0.81 9.94E-07 4.68E-06 1.60E-02 1.97 (1.48-2.60)
10 rs857369 PCDH15 T/C (C) 1 32 270 18 178 684 0.94 0.88 2.29E-06 7.25E-06 5.87E-02 2.33 (1.60-3.39)
10 rs9416306 PCDH15 G/T (T) 1 32 270 18 178 682 0.94 0.88 2.29E-06 7.13E-06 5.88E-02 2.34 (1.61-3.39)
10 rs1219862 PCDH15 C/T (T) 2 31 270 17 182 681 0.94 0.88 2.73E-06 5.08E-06 1.85E-01 2.28 (1.58-3.30)
13 rs7318267 FARP1 C/T (T) 11 149 143 108 387 385 0.72 0.66 6.69E-03 3.15E-01 4.09E-06 3.71 (1.97-7.01)
13 rs2282048 FARP1 T/C (C) 11 148 144 107 387 386 0.72 0.66 5.72E-03 2.84E-01 6.24E-06 3.68 (1.95-6.93)
17 rs1530357 LOC100506974 A/G (A) 57 170 76 114 417 349 0.47 0.37 1.11E-05 4.29E-06 1.39E-02 1.96 (1.45-2.63)
17 rs1530361 LOC100506974 A/G (A) 53 165 85 99 408 372 0.45 0.35 8.83E-06 1.12E-05 7.04E-03 1.54 (1.27-1.86)
19 rs11666971 LASS4 G/A (G) 46 119 138 56 379 445 0.35 0.28 1.64E-03 1.43E-01 8.13E-06 2.63 (1.74-3.96)
  1. aORs and CIs are calculated according to the associated genetic model; bindividuals who developed grade 2 alopecia; cindividuals who did not developed any ADRs after chemotherapy. CHR, chromosome; SNP, single nucleotide polymorphism; ADR, adverse drug reaction; RAF, risk allele frequency; OR, odds ratio; CI, confidence interval.